TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study combining six research cohorts found that older adults with very high levels of the blood biomarker p-tau217 had an estimated 38% chance of developing cognitive impairment within five years and 78% within 10. The 10-year estimate rests on substantially less data, and researchers say current blood tests are not recommended for routine screening of people without symptoms.
Researchers studying 2,684 older adults without cognitive impairment found that very high blood levels of the Alzheimer’s-associated marker p-tau217 were linked to an estimated 38% chance of cognitive impairment within five years and 78% within 10 years. The findings, presented at the Alzheimer’s Association International Conference and published in JAMA, suggest the marker may help estimate future risk, but do not establish that a blood test can diagnose Alzheimer’s or predict an individual’s outcome with certainty; a cleared blood test is intended to aid evaluation.
The research team combined data from six observational studies and clinical trials in North America, Japan and Australia. Participants had no signs of cognitive impairment when they joined the studies. Researchers analyzed blood samples for p-tau217, used PET brain scans to measure baseline brain health, and followed participants with annual assessments of memory, thinking and other cognitive abilities.
Across the combined research, about 478 participants developed cognitive impairment. The investigators found that higher p-tau217 levels were associated with greater likelihood of later impairment. For people with very high levels, the estimated probability reached 38% within five years and 78% within 10 years. The team cautioned that substantially fewer observations were available for the longer period, making the 10-year estimate less certain.
The association remained after researchers accounted for amyloid-beta plaques measured by PET imaging and genetic risk factors including APOE4, according to the study report. The work was led by researchers at the Mass General Brigham Neuroscience Institute. It builds on interest in blood tests that may offer clues to future dementia risk, including a p-tau217 test that has recently received federal clearance; that clearance does not by itself mean the test is recommended to screen people who have no symptoms.
What Risk Estimates Could Add
The study addresses a practical question beyond whether a blood test can detect biological signs linked to Alzheimer’s: whether those signs help estimate the chance of later cognitive problems over a defined period. A blood draw is less burdensome than brain imaging, and a risk estimate could eventually help researchers identify people for prevention trials or support discussions with clinicians.
That possible use is not the same as a proven benefit for patients. The reported percentages describe groups with very high biomarker levels, not a guarantee about what will happen to any one person. The study also does not show that testing healthy people now improves health outcomes. The authors say current preventive advice would not change based on these test results, and they do not recommend routine blood testing for asymptomatic people.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
As an affiliate, we earn on qualifying purchases.
How the Cohorts Were Followed
The analysis drew on studies that began enrolling participants as early as 2004, with the latest follow-up assessments in 2025. That span gave researchers a way to examine cognitive outcomes over several years, although the amount of available information declined at longer follow-up points. The findings therefore offer a risk association over time, rather than a definitive timetable for when symptoms will appear.
Lead author Rachel F. Buckley, a cognitive neuroscientist at Mass General Brigham, said the team harmonized information across six cohorts to estimate risk over time. Senior and corresponding author Reisa Sperling, a neurologist at the institute, said the results should be viewed against the current absence of established disease-modifying treatments for otherwise healthy people identified as being at elevated risk.
“This is a critical step toward better understanding what p-tau217 can tell us about a person’s risk for cognitive impairment.”
— Rachel F. Buckley, lead author and cognitive neuroscientist at the Mass General Brigham Neuroscience Institute
Limits of the Ten-Year Estimate
The 78% estimate at 10 years is less certain than the five-year figure because substantially fewer observations were available for the longer follow-up. The study also included people enrolled in six particular research cohorts; the investigators noted that these participants may not represent the wider population. The supplied report does not give a breakdown of how well the estimates perform across different demographic groups or clinical settings.
The results show an association between p-tau217 and future cognitive impairment, not that the biomarker alone can establish Alzheimer’s disease or determine when a person will develop symptoms. The report does not provide enough detail to assess the test’s accuracy for each individual or to infer that every participant with high levels will become impaired. It also remains unclear how a risk result would change care for an otherwise healthy person while disease-modifying treatments for that group are not established.
Trials May Shape Future Screening
The next practical test of this approach will depend in part on whether ongoing trials of disease-modifying therapies show benefits for people identified before symptoms. Sperling said the preventive-care landscape could change if those trials are successful, potentially giving blood-based risk estimates a role in selecting people who might benefit from treatment. The study report does not specify a timetable for that change.
For now, the authors’ position is that the available blood tests should not be used routinely to screen people without symptoms. Further research will need to test how well these risk estimates apply to broader populations and whether acting on them leads to better outcomes. People considering testing should discuss their circumstances with a qualified health professional rather than treating a biomarker result as a diagnosis.
Key Questions
What did the study find about p-tau217?
Among older adults with very high p-tau217 levels, researchers estimated a 38% chance of cognitive impairment within five years and a 78% chance within 10 years. The longer-term estimate was based on substantially less data.
Does a high result mean someone will develop Alzheimer’s?
No. The study found an association with future cognitive impairment; it does not show that a high result guarantees impairment, provides an exact timeline, or diagnoses Alzheimer’s in a person without symptoms.
Should people without memory problems get this blood test?
The researchers say available blood tests are not recommended for routine screening of asymptomatic people. They note that established disease-modifying treatments for otherwise healthy people identified as being at elevated risk are not yet available.
How reliable is the 10-year risk figure?
The 78% figure is an estimate for people with very high biomarker levels, not a personal prediction. The researchers cautioned that substantially fewer observations were available for the 10-year period, so that estimate is less certain.
Source: sciencedaily.com
